Molecular features of dormancy in ER plus breast cancers

被引：0
|
作者：
Clarke, Robert
Dixon, Michael J.
Jin, Lu
Turnbull, Aaron
Hu, Rong
Zwart, Alan
Wang, Yue
Xuan, Jianhua
Sengupta, Surojeet
Renshaw, Lorna
Sims, Andrew
Liu, Minetta C.
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[2] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[3] Virginia Tech, Arlington, VA USA
[4] Mayo Clin, Rochester, MN USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-04-10
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PTEN Alterations in Advanced ER plus Breast Cancer: Correlation with Clinicopathologic and Molecular Features
    Sweeney, Keith
    Wang, Jing
    Albarracin, Constance
    Roy-Chowdhuri, Sinchita
    Patel, Keyur
    Routbort, Mark
    Ding, Qingqing
    Wu, Yun
    Huo, Lei
    Sahin, Aysegul
    Luthra, Rajyalakshmi
    Chen, Hui
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 198 - 199
  • [2] PTEN Alterations in Advanced ER plus Breast Cancer: Correlation with Clinicopathologic and Molecular Features
    Sweeney, Keith
    Wang, Jing
    Albarracin, Constance
    Roy-Chowdhuri, Sinchita
    Patel, Keyur
    Routbort, Mark
    Ding, Qingqing
    Wu, Yun
    Huo, Lei
    Sahin, Aysegul
    Luthra, Rajyalakshmi
    Chen, Hui
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 198 - 199
  • [3] Prognostic Significance of Multifocal Lesion in ER plus Breast Cancers
    Liang, Y.
    Li, X.
    Wang, J.
    Huo, L.
    Albarracin, C.
    Gong, Y.
    Wu, Y.
    LABORATORY INVESTIGATION, 2014, 94 : 65A - 65A
  • [4] Prognostic Significance of Multifocal Lesion in ER plus Breast Cancers
    Liang, Y.
    Li, X.
    Wang, J.
    Huo, L.
    Albarracin, C.
    Gong, Y.
    Wu, Y.
    MODERN PATHOLOGY, 2014, 27 : 65A - 65A
  • [5] Estrogen drives the therapeutic hormonal response in ER plus breast cancers
    Hugh, Judith
    Haddon, Lacey
    Githaka, John Maringa
    Hu, Xiuying
    Bigras, Gilbert
    Loney, Brittney
    Hanson, John
    Gabos, Zsolt
    Huang, Fleur
    Hitt, Mary
    McManus, Kirk
    Dabbs, Kelly
    Mackey, John
    CANCER RESEARCH, 2020, 80 (04)
  • [6] Molecular characterisation of ER plus breast cancer dormancy and acquired resistance using a clinical model: Potential involvement of epigenetic regulation
    Selli, C.
    Turnbull, A. K.
    Pearce, D.
    Fernando, A.
    Renshaw, L.
    Thomas, J. S.
    Dixon, M. J.
    Sims, A. H.
    CANCER RESEARCH, 2019, 79 (04)
  • [7] Low ER Positive Breast Cancers are Characterized by Aggressive Histologic Features
    Mahmood, Sundis
    Muller, Kristen
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 127 - 128
  • [8] Low ER Positive Breast Cancers are Characterized by Aggressive Histologic Features
    Mahmood, Sundis
    Muller, Kristen
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 127 - 128
  • [9] Expression of estrogen receptor variants in ER plus basal-type breast cancers that respond to therapy like ER- breast cancers.
    Whitworth, Pat W.
    Baron, Paul
    Beitsch, Peter D.
    Yoder, Erin
    Treece, Tina
    Audeh, M. William
    Dinjens, Winand N. M.
    Bernards, Rene
    Groenendijk, Floris
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Examining the prevalence of homologous recombination repair defects in ER plus breast cancers
    Moore, Grace M.
    Powell, Simon N.
    Higginson, Daniel S.
    Khan, Atif J.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (03) : 649 - 653
12345